Henry Doggrell, VP – Chief Legal Officer of GTx, Inc. (GTXI) Just Sold Shares; Clarivest Asset Management Has Raised Its Horizon Bancorp Ind (HBNC) Position

January 10, 2018 - By Jerrie Dane

Clarivest Asset Management Llc increased Horizon Bancorp Ind (HBNC) stake by 65.89% reported in 2017Q3 SEC filing. Clarivest Asset Management Llc acquired 22,601 shares as Horizon Bancorp Ind (HBNC)’s stock declined 4.53%. The Clarivest Asset Management Llc holds 56,901 shares with $1.66M value, up from 34,300 last quarter. Horizon Bancorp Ind now has $686.18 million valuation. The stock increased 0.11% or $0.03 during the last trading session, reaching $26.91. About 76,308 shares traded. Horizon Bancorp (NASDAQ:HBNC) has risen 57.87% since January 10, 2017 and is uptrending. It has outperformed by 41.17% the S&P500.

Gtx Inc VP – Chief Legal Officer and an insider Henry Doggrell recently made a sale of 4,965 company shares worth $56,277 at the average share price of $11.3. Today, Henry Doggrell owns 55,309 shares which make up roughly 0.26% of the company’s market cap.

Analysts await GTx, Inc. (NASDAQ:GTXI) to report earnings on March, 21. They expect $-0.39 earnings per share, up 11.36% or $0.05 from last year’s $-0.44 per share. After $-0.53 actual earnings per share reported by GTx, Inc. for the previous quarter, Wall Street now forecasts -26.42% EPS growth.

Among 3 analysts covering GTx (NASDAQ:GTXI), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. GTx has $17 highest and $0.50 lowest target. $13.33’s average target is 24.12% above currents $10.74 stock price. GTx had 4 analyst reports since August 10, 2016 according to SRatingsIntel. The firm has “Hold” rating by Jefferies given on Friday, December 9. The rating was maintained by Jefferies with “Hold” on Wednesday, August 10.

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. The company has market cap of $231.36 million. It focuses on the development of selective androgen receptor modulators for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). It currently has negative earnings. The company??s lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI.

The stock decreased 2.89% or $0.32 during the last trading session, reaching $10.74. About 26,293 shares traded. GTx, Inc. (NASDAQ:GTXI) has declined 39.61% since January 10, 2017 and is downtrending. It has underperformed by 56.31% the S&P500.

Among 10 analysts covering Horizon Bancorp (NASDAQ:HBNC), 8 have Buy rating, 1 Sell and 1 Hold. Therefore 80% are positive. Horizon Bancorp had 18 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Mkt Perform” rating given on Friday, August 7 by Bruyette & Woods”. The stock of Horizon Bancorp (NASDAQ:HBNC) has “Buy” rating given on Friday, October 6 by Piper Jaffray. As per Friday, July 28, the company rating was maintained by Piper Jaffray. The stock of Horizon Bancorp (NASDAQ:HBNC) earned “Buy” rating by Keefe Bruyette & Woods on Thursday, August 24. The rating was initiated by Piper Jaffray with “Overweight” on Thursday, October 6. As per Friday, August 7, the company rating was upgraded by Bruyette & Woods”. Stephens initiated the stock with “Overweight” rating in Friday, October 2 report. As per Thursday, September 3, the company rating was downgraded by Zacks. Keefe Bruyette & Woods maintained it with “Buy” rating and $31.0 target in Tuesday, October 3 report. The rating was upgraded by FIG Partners to “Outperform” on Monday, March 14.

Investors sentiment increased to 1.7 in 2017 Q3. Its up 0.01, from 1.69 in 2017Q2. It improved, as 2 investors sold HBNC shares while 21 reduced holdings. 6 funds opened positions while 33 raised stakes. 11.20 million shares or 10.81% more from 10.11 million shares in 2017Q2 were reported. Millennium Management Limited Liability Corporation reported 0% stake. Plante Moran Financial Advsrs Ltd invested 0.08% of its portfolio in Horizon Bancorp (NASDAQ:HBNC). Moreover, 1St Source Bancshares has 0.13% invested in Horizon Bancorp (NASDAQ:HBNC). Wells Fargo And Mn holds 58,314 shares. Wellington Management Group Llp owns 1.00M shares for 0.01% of their portfolio. Moreover, Us Fincl Bank De has 0% invested in Horizon Bancorp (NASDAQ:HBNC). Citigroup reported 0% stake. 950,156 are held by Vanguard. Minerva Advsrs Limited Liability invested in 0.46% or 29,816 shares. Brandywine Global Investment Mgmt Limited Liability Co owns 78,035 shares. 40,320 are owned by Thomson Horstmann & Bryant Inc. The Virginia-based Virginia Retirement System Et Al has invested 0% in Horizon Bancorp (NASDAQ:HBNC). State Street invested 0% of its portfolio in Horizon Bancorp (NASDAQ:HBNC). Banc Funds Ltd Liability stated it has 126,143 shares or 0.16% of all its holdings. Amica Mutual Insurance Company stated it has 119,484 shares.

Clarivest Asset Management Llc decreased Netapp Inc (NASDAQ:NTAP) stake by 18,106 shares to 466,658 valued at $20.42 million in 2017Q3. It also reduced Fiserv Inc (NASDAQ:FISV) stake by 11,190 shares and now owns 256,813 shares. Hill Rom Hldgs Inc (NYSE:HRC) was reduced too.